Skip to main content
Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc. — Investor Relations & Filings

Ticker · ANIK ISIN · US0352551081 LEI · 529900R9LS3Z0O6QH455 US Manufacturing
Open in API
Filings indexed 1,017 across all filing types
Latest filing 2024-05-31 Regulatory Filings
Country US United States of America
Listing US ANIK

About Anika Therapeutics, Inc.

https://anika.com/

Anika Therapeutics, Inc. is a global joint preservation company focused on developing, manufacturing, and marketing solutions for early intervention orthopedic care. The company provides a range of therapeutic products and regenerative solutions designed to treat degenerative orthopedic diseases, traumatic conditions, joint pain, and arthritis. Its portfolio, which utilizes technologies such as hyaluronic acid, aims to restore joint function and enable patients to maintain an active lifestyle. Key products include the Integrity™ Implant System, a regenerative scaffold for tendon augmentation. Anika partners with medical professionals to deliver treatments across the continuum of joint care.

Recent filings

Filing Released Lang Actions
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans or inducement plans. It includes details about the registration of additional shares under the company's 2021 Inducement Plan, references prior registration statements, and contains exhibits such as the plan itself and legal opinions. There are no financial statements or earnings data, nor is this a report of financial performance or management discussion. It is a regulatory filing related to securities registration rather than a financial report or announcement of voting results. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7,334 characters) and content confirm it is a full filing, not just a brief announcement or certification.
2024-05-31 English
ANIKA THERAPEUTICS, INC.
Major Shareholding Notification
2024-05-30 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the entry into a material definitive agreement (a Cooperation Agreement), changes in the board of directors (appointment of two new independent directors), a share repurchase program, and related voting and standstill provisions. It also includes a press release and the Cooperation Agreement as exhibits. The document does not contain financial statements or detailed financial analysis but rather announces corporate governance changes and a capital action (share repurchase program). The primary focus is on board changes and a material agreement rather than a full financial report or earnings release. Therefore, the most appropriate classification is "Board/Management Information (MANG)" because it announces changes in the company's board of directors and related governance matters. Confidence is high given the clear description of director appointments and governance agreements in a Form 8-K.
2024-05-28 English
FORM 10-Q
Interim / Quarterly Report Q1 2024
2024-05-08 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is the announcement of the appointment of a new Executive Vice President, Chief Financial Officer, and Treasurer, along with the resignation and transitional arrangements of the previous CFO. This fits the category of changes in senior management or board members. There are no financial statements or detailed financial data presented, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a proxy statement, voting results, or a legal proceeding report. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2024-05-08 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that a press release announcing financial results for the first quarter ended March 31, 2024, is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length of the document is 3778 characters, which is relatively short and consistent with a regulatory announcement rather than a full financial report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but does not contain the full financial data itself. It is not an Earnings Release (ER) because the actual financial results are in the attached press release, and the 8-K is a filing form. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-05-08 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.